



## BioLineRx to Present at 2015 BIO CEO & Investor Conference in New York on February 10

February 3, 2015

JERUSALEM--(BUSINESS WIRE)--Feb. 3, 2015-- BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Executive Officer, Kinneret Savitsky, Ph.D., and its Chief Financial and Operating Officer, Philip Serlin, will present a company update at the 2015 BIO CEO & Investor Conference on Tuesday, February 10, 2015 at 09:00 a.m. EST. The conference will be held at the Waldorf Astoria Hotel in New York.

A live webcast of the presentation will be available on BioLineRx's [website](#). A replay will be available one hour after the presentation ends and will be accessible for three months following the presentation.

Investors or potential partners attending the conference who wish to meet with Dr. Savitsky or Mr. Serlin should contact the BIO Partnering Team at [biopartnering@bio.org](mailto:biopartnering@bio.org).

### About BioLineRx

BioLineRx is a publicly-traded, clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates. The Company in-licenses novel compounds primarily from academic institutions and biotech companies based in Israel, develops them through pre-clinical and/or clinical stages, and then partners with pharmaceutical companies for advanced clinical development and/or commercialization.

BioLineRx's current portfolio consists of a variety of clinical and pre-clinical projects, including: BL-1040 for prevention of pathological cardiac remodeling following a myocardial infarction, which has been out-licensed to Bellerophon BCM (f/k/a Ikaria) and is in the midst of a pivotal CE-Mark registration trial scheduled for completion in mid-2015; BL-8040, a cancer therapy platform, which is in the midst of a Phase 2 study for acute myeloid leukemia (AML) as well as a Phase 1 study for stem cell mobilization; and BL-7010 for celiac disease, which has successfully completed a Phase 1/2 study.

In December 2014, BioLineRx entered into a strategic collaboration with Novartis for the co-development of selected Israeli-sourced novel drug candidates. The companies intend to co-develop a number of pre-clinical and early clinical therapeutic projects through clinical proof-of-concept for potential future licensing by Novartis.

For more information on BioLineRx, please visit [www.biolinerx.com](http://www.biolinerx.com) or download the investor relations mobile device app, which allows users access to the Company's SEC documents, press releases, and events. BioLineRx's IR app is available on the iTunes App Store as well as the Google Play Store.

Source: BioLineRx

[Tiberend Strategic Advisors, Inc.](#)

Joshua Drumm, Ph.D.

+1-212-375-2664

[jdrumm@tiberend.com](mailto:jdrumm@tiberend.com)

or

Andrew Mielach

+1-212-375-2694

[amielach@tiberend.com](mailto:amielach@tiberend.com)

or

BioLineRx

Tsipi Haitovsky

Public Relations

+972-3-6240871

[tsipih@netvision.net.il](mailto:tsipih@netvision.net.il)